Lv21
148 积分 2026-04-09 加入
Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers
1个月前
已完结
Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia
1个月前
已完结
A cocrystal-based long-acting injectable suspension platform enables tunable drug release
1个月前
已完结
Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
3个月前
已完结
Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic. Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
3个月前
已完结
Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist
3个月前
已完结
Cebranopadol:a first in-class example of a nociceptin/orphanin FQ receptor and opioid agonist
3个月前
已完结
Optimizing Treatment With Aripiprazole Monohydrate
5个月前
已完结
Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder
5个月前
已完结
皖公网安备34019202002308
